logo

Merus B.V. (MRUS)



Trade MRUS now with
  Date
  Headline
5/24/2018 7:05:40 AM Merus Announces First Patient Dosed In Phase 1 Trial Of MCLA-158 In Patients With Solid Tumors
4/30/2018 9:20:55 AM Wedbush Is Increasing Merus B.V. (MRUS) FY18 Estimate To -3.29 From -3.78
4/30/2018 9:20:41 AM Wedbush Is Increasing Merus B.V. (MRUS) Q4 18 Estimate To -0.94 From -1.07
4/30/2018 9:20:26 AM Wedbush Is Raising Merus B.V. (MRUS) Q3 18 Estimate To -0.86 From -0.98
4/30/2018 9:20:07 AM Wedbush Is Raising Merus B.V. (MRUS) Q2 18 Estimate To -0.78 From -0.90
4/30/2018 9:19:52 AM Wedbush Is Increasing Merus B.V. (MRUS) Q1 18 Estimate To -0.72 From -0.83
4/30/2018 9:19:07 AM Wedbush Reiterates Merus B.V. (MRUS) At Outperform With $26 Down From $32 Price Target
3/14/2018 7:11:31 AM Merus Announces Ono Exercised Its Option For New Research And License Agreement
3/13/2018 7:04:26 AM Merus Expands Intellectual Property Portfolio With Two Newly Issued U.S. Patents
1/26/2018 7:04:48 AM Merus Announces First Patient Dosed In A Phase 2 Clinical Trial Of MCLA-128 In Two MBC Patient Populations
1/12/2018 9:03:23 AM Wedbush Reiterates Merus B.V. (MRUS) At Outperform With $32 Price Target
1/8/2018 7:12:50 AM Merus, Simcere Announce Strategic Collaboration On Multiple Bispecific Antibodies
1/4/2018 7:05:35 AM Merus Announces Submission Of IND Application To FDA For MCLA-117
12/27/2017 7:36:52 AM Merus: Court Of Appeals Denies Regeneron' Petition To Rehear Panel' Decision Affirming Merus'Inequitable Conduct Claim
11/30/2017 7:07:17 AM Merus Q3 Net Loss EUR 15.7 Mln Or EUR 0.81/Shr Vs Loss EUR 4.9 Mln Or EUR 0.31/Shr Last Year
9/20/2017 7:35:37 AM Merus Adds Two New U.S. Patents Related To Its Proprietary Biclonics Technology
9/19/2017 4:09:34 PM Merus Q2 Loss/share EUR 1.12 Vs. Loss EUR 0.40 Year Ago
7/11/2017 4:09:10 PM Merus Q1 Loss/share EUR 1.15 Vs. Loss EUR 0.63 Year Ago